original articlessarcomas and melanomaFour-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
sarcomas and melanoma
Under an Elsevier user license
open archive
Keywords
cytotoxic T-lymphocyte antigen-4
immunotherapy
ipilimumab
long-term survival
metastatic melanoma
survival rate
Cited by (0)
- †
Present address: MethylGene, Inc., Montreal, Quebec, Canada.
Copyright © 2013 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.